Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.

Recs

0
Player Avatar Antevorte (< 20) Submitted: 1/10/2011 11:31:40 AM : Outperform Start Price: $14.40 AMLN Score: +48.69

As I see it, yes

Featured Broker Partners


Advertisement